INTRODUCTION
Worldwide, the number of people newly infected with HIV continues to fall, with a 20% reduction in HIV acquisition between 2001 and 2011 [1] . This heartening progress suggests that the global HIV pandemic has passed peak incidence [1, 2] . Such progress may have transpired because of two major advancements: substantially increased access to antiretroviral therapy (ART) has increased global coverage by 63%, thereby contributing to decreased HIV transmission (i.e., HIV treatment as prevention) [3] , and increased availability and access to HIV combination prevention (e.g., behavioral and biomedical) [4] .
Despite this progress, recent reports depict a different reality in some regions. For example, reductions in new HIV infections are uneven because of injection drug use (IDU) and non-IDU in a number of low-income and middle-income countries [1,3,4,5 && ,6]. In the last several years, increases in injection and noninjection drug use have affected HIV risks and HIV incidence among key subpopulations, including females who inject drugs (FWIDs), FWIDs who engage in sex work, non-IDU sex partners of people who inject drugs (SP-PWIDs), young people who inject drugs, and noninjection drug users.
The Joint United Nations Programme on HIV/ AIDS (UNAIDS) identified nine countries where HIV incidence increased 25% or more between 2001 and 2011 [2, 3] . In six of these countries, the majority of which are in Eastern Europe and Central Asia [2, 3] , IDU was the major mode of HIV transmission. Although the highest concentration of people who inject drugs (PWIDs) remains in Eastern Europe and Central Asia [7] , Southeast Asia and some countries in Africa, including Kenya, Tanzania, Nigeria, Mauritius, and South Africa [8, 9] , are experiencing increases in the number of PWIDs. Furthermore, the emergence of some forms of noninjection substance use (particularly stimulants) is occurring in a number of countries including parts of Africa. This rise of non-IDU may also be driving HIV transmission, because of the associations between substance use and sexual risk behaviors [4, [10] [11] [12] 13 && ]. This article focuses on the studies published in 2012-2013 that consider re-emerging and emerging injection and noninjection drug use as drivers of HIV transmission among FWIDs, FWIDs who engage in commercial sex work, non-IDU SP-PWIDs, young PWIDs, and noninjection drug users; structural risk environments that promote injection and noninjection drug use as drivers of HIV risk among key subpopulations; and prevention and policy strategies to address the growing concerns and challenges related to these trends.
DRUG-USING POPULATIONS AND THE HIV EPIDEMIC
Both injection and noninjection drug use are drivers of HIV infection among key populations. Drug use may lead to HIV transmission through shared syringes and drug equipment, unprotected sex while under the influence of drugs, and the influence of drug use, which can lead to heightened sexual activity and impaired judgment [10] [11] [12] 13 && ,14]. Moreover, sex and roles and social norms about condom use and drug sharing may influence HIV risk behavior.
IDU risks for HIV transmission are of growing concern among the following four populations.
Females who inject drugs
Recent reports show that the number of FWIDs has increased in many countries [3, 7] . In countries where HIV prevalence is higher than 20% among FWID, Des Jarlais et al. [15 && ] found that HIV prevalence was significantly higher among FWIDs than men who inject drugs (MWID). This finding was consistent across 117 studies that included 128 745 PWIDs in 14 countries. In Thailand, where this trend was also observed, higher levels of risk behaviors were also found among FWIDs when compared with MWID, including less frequent use of sterile needles and condoms [16] . One explanation for the sex disparity in HIV prevalence is that FWIDs are more likely to have sex partners who also inject drugs, placing them at higher risk for acquiring HIV through drug or sexual risk behaviors with their partners, whereas MWID are more likely to have sex partners who do not inject drugs [14, 17] . Moreover, studies have identified sex-associated economic and social inequalities within the drug cultures of many countries. For example, men often influence women's drug use by introducing them to drug injection and providing drugs, contributing to social network insularity [18] . Many FWIDs rely on their sexual partners for access to drugs and hence lack control over injection equipment [19] . Condom use remains low among some FWIDs and their main partners, and condoms may be used less often when couples adhere to the traditional sex roles [20] . These problems are further complicated by the fact that FWIDs in some countries face greater challenges than MWID in obtaining sterile injection equipment and accessing harm reduction programs [15 && ], because of the reliance on intimate partners to access resources including needles [21, 22] and greater levels of discrimination experienced when seeking HIV and drug use treatment [7] .
Females who inject drugs and trade sex
Overlap between IDU and sex work is common worldwide [6, [23] [24] [25] . Sex work has emerged as a major driver of HIV among FWIDs in Eastern Europe and Central Asia [24] [25] [26] [27] , where the dual risks of injection and sex trading influence the HIV transmission [19,28 & ]. Consistent access to drugs in these regions has led to increases in the number of women injecting drugs and increased engagement in sex trading due in part to difficulties maintaining other employment as a result of drug use [29] .
A systematic review with data from 77 countries showed that the percentage of adult HIV-infected sex workers was a strong predictor of national adult HIV prevalence [24] . FWIDs who trade sex may struggle to protect themselves from HIV because of sexual and physical abuse from clients, police,
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and their intimate sexual partners [30] . Condom use among women who trade sex is often inconsistent because of the clients' preferences for unprotected sex, and women who trade sex tend to not use condoms with their intimate partners [25, 27, 31] . Furthermore, FWIDs who trade sex face social structural barriers that impede their access to HIV prevention such as a lack of access to healthcare and HIV services, poverty, criminalization of sex work, imprisonment, and the confiscation of condoms as evidence of commercial sex work [25, 27, 31] . This situation underscores the urgent need to address sexual and drug risks and structural barriers to HIV prevention services and policies for FWIDs who trade sex.
Sexual partners of people who inject drugs
In many parts of the world where IDU has been a major driver of the HIV epidemic, sexual transmission of HIV from PWIDs to their sexual partners has increased [5 && ,11,32] . IDU-concentrated epidemics are likely to have initiated heterosexually transmitted epidemics in Argentina, Brazil, China, Indonesia, the Netherlands, and Ukraine [5 && ]. Most of these countries have had fewer resources for PWIDs and higher levels of stigmatization toward PWIDs when compared with countries where this transition was not observed (Italy, Scotland, Spain, France, and Thailand). Indonesia in particular saw a 10-fold increase in the HIV incidence between 2006 and 2011 [33] . In 2011, heterosexual transmission represented half of all new HIV infections in Kazakhstan [34, 35] , suggesting that a transition from IDU-concentrated epidemics to heterosexual HIV epidemics [5 && ] is occurring in Central Asia. Condom use between PWIDs and their sex partners remains low [14, 20, 36] , and noninjecting female sex partners may be at particular risk [17] . This growing key population has not received sufficient attention in HIV prevention, especially in low-income and middle-income countries.
The extent to which MWID transmit HIV to male sexual partners is understudied, but is important in regions where IDU is endemic, particularly when homosexuality is illegal or highly stigmatized [25] . Recent legislation against homosexuality in Russia Young people who inject drugs HIV incidence increased by 20% among young people (age [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] in Eastern Europe between 2001 and 2011; the majority of this HIV-infected subpopulation injects drugs [3,39 & ]. A recent review of studies conducted in Ukraine indicated that the youth who were homeless and orphaned were more likely to be HIV positive and to engage in injecting drug use, compared with youth with stable housing who resided with their parents [40] . In Western countries, adolescents have reported the use of emerging drugs such as synthetic cannabinoids (e.g., 'Spice') and cathinones (e.g., 'bath salts'), and over-the-counter cough medicine dextromethorphan has gained popularity in Thailand among middle and high school students [41] . The extent to which these substances affect the sexual behaviors such as condom use are unknown [13 && ]. Age-appropriate HIV prevention services are needed for young people who use drugs, as are additional studies to inform prevention development.
Noninjection drug use
The last decade has witnessed the emergence and acceleration of different noninjection drugs in some regions of the world. Certain noninjection drugs, particularly stimulants, lead to an elevated rate of HIV transmission because of their association with high-risk sexual behaviors [25, 26] .
In Brazil and other South American countries, cocaine injection was prevalent in the late 1980s and heroin injection was prevalent in the 1990s, whereas methamphetamine smoking is currently emerging [13 && ]. Methamphetamine plays a role in HIV transmission in that it leads to increased sexual activity, impaired decisionmaking, and inconsistent condom use [42, 43] . Use of amphetamine-type stimulants, specifically methamphetamine, has increased in many countries within East and Southeast Asia [44] . A recent study among PWIDs in Bangkok found that the availability of heroin, methamphetamine, crystal methamphetamine, midazolam, and illicit methadone increased substantially between 2009 and 2011 [45] .
Heroin, methamphetamine, and methcathinone use has also increased in South Africa [7, 46, 47] . Other countries in sub-Saharan Africa have witnessed the epidemics of heroin and cocaine use [8, 14, 46] , especially among FWIDs who trade sex [48] . Recently, West Africa came to the fore as a drop-off point on a major cocaine trafficking route from South America to Western and Central Europe. High rates of cocaine and heroin use in Nigeria may result from the country's role in drug trafficking [9] . West African drug trafficking organizations which historically have focused on cocaine and heroin have become increasingly involved in trafficking methamphetamine, using diverse methods to avoid detection [44] .
New compounds derived from the parent substances like cocaine and heroin have emerged through efforts to avoid laws addressing drug possession and distribution [49] . The use of these compounds is increasing in many countries including Eastern Europe and Central Asia, both of which have seen the arrival of heroin synthetic substitutes and homemade drugs such as krokodil [50, 51] . Krokodil use has increased in Russia, Kazakhstan, and Ukraine because of changes in heroin availability, purity, and price, all of which are associated with heroin 'droughts,' police interdiction, legislative changes targeting poppy imports, and rising poverty levels in Russia since the 2008 global economic downturn [52] . In the last 3-5 years, an increasing number of reports suggest that drug producers in Russia, Ukraine, and other countries are making drugs with over-the-counter medications that contain codeine instead of poppies or raw opium as a starting material [44, 53, 54] . Knowledge about how these newer substances affect sexual behavior is lacking [55] and needs research attention.
STRUCTURAL RISK ENVIRONMENTS
Common structural risk environments affect the reemergence and emergence of IDU and HIV epidemics in some countries, including lack of access to treatment and prevention services. Few HIV prevention efforts exist in low-income and middle-income countries, where resources for drug treatment programs and ART are limited. Low levels of committed resources in national healthcare budgets leave dependence on international donor support for harm reduction programming [1] . As a result, harm reduction program coverage remains low, especially in regions where HIV is spreading rapidly [2,39 & ,56] . Opioid substitution therapy (OST) has yet to become widely available in Eastern Europe and Central Asia, where rates of IDU are high. Political opposition in Kazakhstan delayed the introduction and scale-up of nationwide OST programs [34] , and in Uzbekistan, an OST pilot project was declared ineffective prematurely, accompanied by denial of the evidence supporting OST's effectiveness at reducing HIV [34] . In Russia, OST remains illegal [56] .
In addition to the lack of funding and support for harm reduction services, government policies that criminalize and restrict the access to needle exchange programs and nongovernmental health organization services may lead to arrests of harm reduction service clients, physical abuse or the extraction of bribes in response to possession of syringes and needles [57, 58] , or sexual exploitation of FWIDs and sex workers who inject drugs by police [59] . Effective HIV programs require cooperation from law enforcement officials, but relationships between drug users and the police are problematic in many countries. Many countries in Eastern Europe and Central Asia have official registries of persons known to be addicted to drugs. Registered persons lose important civil rights, are subject to police brutality, and are therefore often reluctant to participate in HIV prevention services [58, 60] . Even carrying sterile needles and syringes can be risky for PWIDs as they may be arrested for paraphernalia possession [61 & ,62]. Police education programs promoting harm reduction approaches with occupational safety (i.e., concerns about needle stick injuries) may be a useful avenue for addressing stigma and abuse from the police toward injecting drug users. Beletsky et al. [63] recently showed that a police education program implemented in Kyrgyzstan was associated with officers being significantly more likely to support referring individuals to public health organizations, express no intent to confiscate syringes (adjusted odds ratio 1.92; 95% confidence interval 1.09-3.39), better understand sex worker detention procedures, and have higher knowledge regarding occupational safety [63] .
An alarming context of structural risk is also impacting HIV acquisition in Greece. Prior to 2011, the HIV epidemic was concentrated among men who have sex with men. However, Greece saw a 15-fold increase in the HIV incidence among PWIDs in 2011 [64, 65] . This drastic change in HIV incidence likely occurred as a result of the economic collapse in 2007, demonstrating the impact of poor economic conditions on HIV risk behaviors [66] .
Multilevel risk environments including economic and political conditions also play a role in fostering new drug trafficking routes, new drug compounds, and the emergence of non-IDU. Noninjection drug users, like PWIDs, may experience risk environments, including stigma, discrimination, incarceration, homelessness, lack of health insurance, harsh drug policies, and lack of access to drug treatment and HIV prevention and services [13 && ,67] . These risk environments may contribute to HIV transmission, drug overdose, and death among people who use drugs [68 & ].
CONCLUSION
The challenges facing key populations highlighted in this article (FWIDs, FWIDs who trade sex, SP-PWIDs, young PWIDs, and noninjection drug users) are the cause for global concern. The literature highlights the re-emergence and emergence of injection and noninjection drug use as major drivers of HIV transmission, demonstrating that HIV epidemics occur within the contexts of global economic and political forces, including poverty, human rights violations, discrimination, drug policies, trafficking practices, and other multilevel risk environments.
Research over the last few years has called for more attention to these key populations, especially in low-income and middle-income countries, and has stressed the importance of improving access to HIV behavioral and biomedical prevention, HIV treatment strategies (i.e., early initiation of ART, preexposure prophylaxis, etc.), OST, and syringe exchange programs. Whereas some high-income countries have developed and implemented successful harm reduction programs, in most low-income and middle-income countries, harm reduction operates at subthreshold levels. HIV prevention research on substance-using populations has focused primarily on PWIDs; however, most abused substances are administered through noninjection methods (e.g., snorting, smoking, inhaling, and ingestion) [13 && ]. Like PWIDs, noninjection drug users have been excluded from many trials on HIV combination prevention because of the concerns over potential medication adherence problems [13 && ]. However, combination HIV prevention approaches that address non-IDU are needed.
This article advances several recommendations for change: commitment by policy makers, funders, and governments is necessary to secure access to evidence-based and optimal HIV and drug treatment programs, including increased access to combination prevention approaches for PWIDs, SP-PWIDs, FWIDs who trade sex, young PWIDs, and people who use noninjection drugs; specific contexts and drivers of re-emerging and emerging injection and noninjection drug use (e.g., drug trafficking, drug policies, economic collapse, stigma, and discrimination against drug users) must be addressed on local levels with international partnerships and support; efforts should be made to reduce stigmatization by policy makers and service providers, setting aside biases that limit the service availability and effectiveness and ensuring human rights protection for people who use or inject drugs; and there is a serious need for comprehensive data collection on drug use and HIV throughout the world, specifically in low-income and middleincome countries. Thus far, in many low-income and middle-income countries, no accurate estimates exist to indicate how many people use or inject drugs and no accurate surveillance systems exist. Reliable data are essential for policy makers to make informed decisions regarding the drug policies and improved access to HIV and drug treatment services for these key populations [67] .
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